CD133 offers an exciting accessibility to, not only separate stem cells from tissues (i.e., bone marrow), [20–22], but also to isolate cancer stem cells from tumors by using monoclonal antibodies against CD133 [22, 23]. This evidence concerns the gene PROM1 and cancer.